Prior to joining Taiwania, Michael was the co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the development of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed out-licensing deals with Sihuan Pharmaceutical and Sanofi Korea.
Michael had over 18 years of experience as a venture capitalist, focusing on investments in life science startups in the US, Taiwan, and Japan. Some of his notable deals include Coley Pharmaceuticals, Inc. (acquired by Pfizer), MediciNova (MNOV, OSE:4875), Nellix, Inc.(acquired by Endologix), Mycenax Biotech, Inc. (TPEx), PharmaEngine, Inc. (TPEx), Apex International Co. (Acquired by Parexel), Frequency Therapeutics, Inc. (FREQ).
Michael’s expertise is in investing and managing early to late-stage biotech and medical device companies in Greater China, Japan, European and North America regions.